Aeglea BioTherapeutics Inc (AGLE)


Stock Price Forecast

Nov. 27, 2023


Forecasted Returns

7 Days Predict

30 Days Predict

90 Days Predict


Forecasted Market-Excess Returns

7 Days Predict

30 Days Predict

90 Days Predict

Loading Aeglea BioTherapeutics Inc chart...

About the Company

aeglea was founded in december of 2013 to develop engineered human enzymes invented in the laboratory of george georgiou, ph.d. of the university of texas at austin. the convergence of discovery and technology has created a significant opportunity for aeglea to impact both the treatment of inborn errors of metabolism and cancer. three drug candidates that degrade specific amino acids in the circulation are in development. for inborn errors of metabolism efforts are underway to normalize high arginine levels in patients who suffer from a gene mutation in the arginine degrading enzyme arginase1 and for patients who have mutations leading to excess levels of homocysteine. taking advantage of a cancer’s metabolic vulnerability and selectively killing only the tumor through deprivation of arginine, cysteine/cystine, and methionine are techniques in development for multiple oncology indications. coupling amino acid depletion therapy with the development of diagnostics for each oncology f

Exchange

NASDAQ

Website

aegleabio.com

$186M

Total Revenue

83

Employees

$49M

Market Capitalization

-2.61

Price/Earning ratio

Fundamental Data and Insider Transactions (Quarterly data) Full Screen

Loading the fundamentals chart...

Latest $AGLE News

Aeglea BioTherapeutics (NASDAQ: AGLE)

3d ago, source: The Motley Fool

Aeglea Biotherapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development of next-generation human enzyme therapeutics as disruptive solutions for rare and other ...

Spyre Therapeutics Enhances Protection for Executives and Board

1mon ago, source: Hosted on MSN

Spyre Therapeutics, Inc. has introduced a new indemnification agreement for its board members and executive officers, replacing previous arrangements from its predecessor, Aeglea BioTherapeutics ...

Spyre Therapeutics Inc (SYRE)

10d ago, source: Investing

Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE) announced new positive phase I/II data for pegzilarginase in patients with Arginase 1 Deficiency (ARG1-D), a rare genetic disease. The ...

Spyre Therapeutics Privately Places $180 Mln Of Shares; Stock Up In Pre-Market

18h ago, source:

Spyre Therapeutics, Inc. (SYRE), a company focused on inflammatory bowel disease on Monday said it entered into a deal for a private ...

Lilly Ventures Fund I LLC's Net Worth

4d ago, source: Benzinga.com

Who is Lilly Ventures Fund I LLC? Lilly Ventures Fund I LLC has an estimated net worth of $18 Million. This is based on reported shares across multiple companies, which include Coherus BioSciences ...

SAB Biotherapeutics Inc SABS

3d ago, source: Morningstar

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings ...

Arcutis Biotherapeutics Inc

3mon ago, source: CNN

Arcutis Biotherapeutics, Inc. engages in the development and commercialization of treatments for dermatological diseases. Its pipeline consists of topical treatments for plaque psoriasis ...

Northwest Biotherapeutics Inc NWBO

5d ago, source: Morningstar

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Q4 2023 Iovance Biotherapeutics Inc Earnings Call

19d ago, source: Yahoo Finance

Sara Pellegrino; Senior Vice President, Investor Relations and Corporate Communications; Iovance Biotherapeutics Inc Frederick Vogt; Interim President and Chief Executive Officer; Iovance ...

Iovance Biotherapeutics Inc (IOVA)

11h ago, source: Investing

Iovance Biotherapeutics, Inc., a commercial-stage biotechnology company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic ...

Latest Neutral (free) Forecasts

STRONG BUY BUY NEUTRAL SELL STRONG SELL ALL

Loading the latest forecasts...

My Portfolio

Loading your portfolio...